These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 7574783

  • 21. Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma.
    Kirkwood JM, Wilson J, Whiteside TL, Donnelly S, Herberman RB.
    Cancer Immunol Immunother; 1997 May; 44(3):137-49. PubMed ID: 9191873
    [Abstract] [Full Text] [Related]

  • 22. [Synergistic activation of rat alveolar macrophages by cepharanthine and OK-432].
    Morioka S, Ono M, Tanaka N, Orita K.
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1470-5. PubMed ID: 4015121
    [Abstract] [Full Text] [Related]

  • 23. [Skin reaction to OK-432 and its dosage for locoregional administration].
    Yamaguchi Y, Noma K, Miyahara E, Funakoshi M, Takashima I, Kawami H, Sawamura A, Toge T.
    Gan To Kagaku Ryoho; 1994 Sep; 21(13):2108-10. PubMed ID: 7944414
    [Abstract] [Full Text] [Related]

  • 24. [The effect of endogenous tumor necrosis factor (TNF)-induction therapy in the model of VX-2 ovarian carcinoma in the rabbit].
    Hirata S.
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Nov; 42(11):1477-83. PubMed ID: 2273301
    [Abstract] [Full Text] [Related]

  • 25. Local delivery system of immune modulating drug for unresectable adenocarcinoma: in vitro experimental study and in vivo animal study.
    Lee DH, Kang SG, Jeong S, Yoon CJ, Choi JA, Byun JN, Park JH, Lee KB.
    Cardiovasc Intervent Radiol; 2006 Nov; 29(5):832-7. PubMed ID: 16779692
    [Abstract] [Full Text] [Related]

  • 26. A streptococcal preparation (OK-432) enhances monoclonal antibody NCC-ST-421 cytotoxicity against human colon cancer.
    Kawano Y, Watanabe M, Kubota T, Nishibori H, Kurihara N, Teramoto T, Kitajima M.
    Anticancer Res; 1997 Nov; 17(4A):2449-53. PubMed ID: 9252661
    [Abstract] [Full Text] [Related]

  • 27. [Changes in cytokine levels in ascitic fluid after intraperitoneal administration of OK-432].
    Terashima M, Takagane A, Abe K, Kuboi M, Asahi H, Saito K.
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1443-5. PubMed ID: 8373202
    [Abstract] [Full Text] [Related]

  • 28. Induction of interferon-gamma and tumor necrosis factor in ascites of a patient with ovarian cancer by OK-432.
    Mori H, Itoh N, Shiraki S, Tamaya T.
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Apr; 40(4):497-8. PubMed ID: 3131464
    [No Abstract] [Full Text] [Related]

  • 29. Down-regulation of IL-10 enhances the efficacy of locoregional immunotherapy using OK-432 against malignant effusion.
    Hihara J, Yamaguchi Y, Minami K, Noma K, Toge T.
    Anticancer Res; 1999 Apr; 19(2A):1077-84. PubMed ID: 10368657
    [Abstract] [Full Text] [Related]

  • 30. The immunostimulant OK-432 enhances liver regeneration after 90% hepatectomy in rats.
    Kato K, Matsuda M, Kusano M, Onodera K, Kato J, Kasai S, Mito M, Hodgson WJ.
    Hepatology; 1994 May; 19(5):1241-4. PubMed ID: 8175147
    [Abstract] [Full Text] [Related]

  • 31. Mature dendritic cells generated from patient-derived peripheral blood monocytes in one-step culture using streptococcal preparation OK-432 exert an enhanced antigen-presenting capacity.
    Naito K, Ueda Y, Itoh T, Fuji N, Shimizu K, Yano Y, Yamamoto Y, Imura K, Kohara J, Iwamoto A, Shiozaki A, Tamai H, Shimizu T, Mazda O, Yamagishi H.
    Int J Oncol; 2006 Jun; 28(6):1481-9. PubMed ID: 16685449
    [Abstract] [Full Text] [Related]

  • 32. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Nakamori M, Ueda K, Naka T, Katsuda M, Miyazawa M, Iida T, Yamaue H.
    Int J Oncol; 2008 Feb; 32(2):459-66. PubMed ID: 18202769
    [Abstract] [Full Text] [Related]

  • 33. Stable long-term induction of perforin-positive CD8+ T cells in gut by oral administration of streptococcal preparation OK-432.
    Mino N, Naomoto Y, Shirakawa Y, Matsuoka J, Nobuhisa T, Gunduz M, Noma K, Nagatsuka H, Kobayashi M, Yamatsuji T, Haisa M, Gochi A, Tanaka N.
    Int J Mol Med; 2004 Nov; 14(5):801-6. PubMed ID: 15492848
    [Abstract] [Full Text] [Related]

  • 34. Oral administration of a streptococcal agent OK-432 activates peritoneal macrophages in mice.
    Suzuki I, Kinoshita A, Tanaka H, Yadomae T.
    Int J Immunopharmacol; 1991 Nov; 13(2-3):147-54. PubMed ID: 2071291
    [Abstract] [Full Text] [Related]

  • 35. Immunopotentiating action of streptococcal preparation OK-432 and protein-bound polysaccharide PS-K on depressed state of cell-mediated and humoral immunities of Friend leukemia virus infected mice.
    Kiyohashi A.
    Nihon Gan Chiryo Gakkai Shi; 1981 Aug 20; 16(4):641-6. PubMed ID: 7328350
    [No Abstract] [Full Text] [Related]

  • 36. The biological response modifier OK-432 (a streptococcal preparation) inhibits the development of autoimmune kidney disease in NZB/W F1 hybrid mice: possible involvement of tumor necrosis factor.
    Mihara M, Ohsugi Y.
    Int Arch Allergy Appl Immunol; 1989 Aug 20; 90(1):37-42. PubMed ID: 2807578
    [Abstract] [Full Text] [Related]

  • 37. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide.
    Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H.
    Cancer Res; 2003 Jul 15; 63(14):4112-8. PubMed ID: 12874015
    [Abstract] [Full Text] [Related]

  • 38. [Changes of cytokine levels in ascitic fluid after intraperitoneal administration of OK-432 or CDDP].
    Terashima M, Takagane A, Abe K, Kuboi M, Asahi H, Saito K.
    Gan To Kagaku Ryoho; 1994 Sep 15; 21(13):2326-9. PubMed ID: 7944471
    [Abstract] [Full Text] [Related]

  • 39. Augmentation of interleukin 1 and interleukin 2 production by OK-432.
    Ichimura O, Suzuki S, Saito M, Sugawara Y, Ishida N.
    Int J Immunopharmacol; 1985 Sep 15; 7(2):263-70. PubMed ID: 3874175
    [Abstract] [Full Text] [Related]

  • 40. Inhalation therapy using a streptococcal preparation (OK-432) against bronchioloalveolar carcinoma of the lung.
    Yano T, Ichinose Y, Yokoyama H, Fukuyama Y, Sugio K, Sugimachi K.
    Anticancer Res; 1999 Sep 15; 19(6C):5511-4. PubMed ID: 10697608
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.